Article    Table of Contents                    Full Text of this article Free    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Sekul, E. A.    Dalakas, M. C.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors

Elizabeth A. Sekul; Edward J. Cupler; and Marinos C. Dalakas

15 August 1994 | Volume 121 Issue 4 | Pages 259-262

Objective: Intravenous immunoglobulin is widely used to treat various autoimmune disorders. After observing instances of aseptic meningitis in treated patients, we studied the frequency and associated risk factors for aseptic meningitis in patients treated with high-dose intravenous immunoglobulin.

Design: Retrospective analysis of a prospective cohort study.

Setting: Tertiary research referral center.

Patients: 54 consecutive patients with various immune-related neuromuscular diseases participating in ongoing therapeutic trials of high-dose (2 g/kg) intravenous immunoglobulin.

Measurements: Analysis of patient records for evidence of aseptic meningitis, associated risk factors, penetration of serum IgG into the cerebrospinal fluid, and clearance of cerebrospinal fluid IgG.

Results: Of 54 patients, 6 (11%; 95% CI, 4% to 23%) developed aseptic meningitis within 24 hours after completion of the infusions. Symptoms, lasting 3 to 5 days, included severe headache, meningismus, photophobia, and fever. Cerebrospinal fluid showed pleocytosis in 4 patients (leukocyte count as high as 1169 x 10⁶/L in one patient), eosinophilia in 3 patients, and IgG elevation in all patients (as great as 7 times the upper limit of normal in one patient). Repeat cerebrospinal fluid and serum studies after 24 hours showed a 46% cerebrospinal fluid IgG clearance compared with an 11% clearance of serum IgG in one patient. Cerebrospinal fluid cultures were negative. Aseptic meningitis developed in 4 of 8 patients (50%; CI, 16% to 84%) with a history of migraine but in only 2 of 46 (4%; CI, 0.5% to 15%) patients without such a history (P = 0.003). Aseptic meningitis recurred in patients who had migraine despite the use of different commercial intravenous immunoglobulin preparations and slower rates of infusion.

Conclusion: Aseptic meningitis develops in patients receiving high-dose intravenous immunoglobulin therapy. Patients with a history of migraine are more likely to develop aseptic meningitis while receiving intravenous immunoglobulin therapy, regardless of the type of commercial preparation or the infusion rate. Possible inciting factors include the IgG itself, various stabilizing products within each of the preparations, cytokine release triggered by the therapy, or cerebrovascular sensitivity in migraineurs.

Author and Article Information

From the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
Requests for Reprints: Marinos C. Dalakas, MD, Neuromuscular Diseases Section, National Institutes of Health, Building 10, Room 4N248, 9000 Rockville Pike, Bethesda, MD 20892.

Related articles in Annals:

Editorials
Aseptic Meningitis and Intravenous Immunoglobulin Therapy
Curtis L. Scribner, Richard M. Kapit, Evelyne T. Phillips, AND Nathaniel M. Rickles

Annals 1994 121: 305-306. [Full Text]  

This article has been cited by other articles:

				H. M Gurcan and A R. Ahmed Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid Ann. Pharmacother., October 1, 2007; 41(10): 1604 - 1610. [Abstract] [Full Text] [PDF]

				S. Jarius, P. Eichhorn, M. H. Albert, S. Wagenpfeil, M. Wick, B. H. Belohradsky, R. Hohlfeld, D. E. Jenne, and R. Voltz Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNF{alpha}-dependent and Fc-receptor-independent way Blood, May 15, 2007; 109(10): 4376 - 4382. [Abstract] [Full Text] [PDF]

				H. M Gurcan and A R. Ahmed Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders Ann. Pharmacother., May 1, 2007; 41(5): 812 - 823. [Abstract] [Full Text] [PDF]

				D Singh-Grewal, A Kemp, and M Wong A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions Arch. Dis. Child., August 1, 2006; 91(8): 651 - 654. [Abstract] [Full Text] [PDF]

				G. Vecchietti, K. Kerl, C. Prins, G. Kaya, J.-H. Saurat, and L. E. French Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol, February 1, 2006; 142(2): 213 - 217. [Abstract] [Full Text] [PDF]

				A. Wada, R. Yoshida, K. Oda, E. Fukuba, N. Uchida, and H. Kitagaki Acute Encephalopathy Associated with Intravenous Immunoglobulin Therapy AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2311 - 2315. [Abstract] [Full Text] [PDF]

				F. J. DiMario Jr Intravenous Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial Pediatrics, July 1, 2005; 116(1): 226 - 228. [Full Text] [PDF]

				M. C. Dalakas Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases JAMA, May 19, 2004; 291(19): 2367 - 2375. [Abstract] [Full Text] [PDF]

				G. Zhang, P. H. H. Lopez, C. Y. Li, N. R. Mehta, J. W. Griffin, R. L. Schnaar, and K. A. Sheikh Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies Brain, May 1, 2004; 127(5): 1085 - 1100. [Abstract] [Full Text] [PDF]

				B. C. Jacobs, G. M. O'Hanlon, R. W. M. Bullens, J. Veitch, J. J. Plomp, and H. J. Willison Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding Brain, October 1, 2003; 126(10): 2220 - 2234. [Abstract] [Full Text] [PDF]

				M. C. Dalakas Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies Neurology, December 24, 2002; 59(90126): S13 - 21. [Abstract] [Full Text]

				T. H. Brannagan III Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S33 - 40. [Abstract] [Full Text]

				K. Sudo, Y. Tajima, A. Matsumoto, C. Solaro, and M. C. Dalakas High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome N. Engl. J. Med., May 30, 2002; 346(22): 1747 - 1748. [Full Text] [PDF]

				C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]

				S. Schmaldienst, M. Mullner, A. Goldammer, S. Spitzauer, S. Banyai, W. H. Horl, and K. Derfler Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology, May 1, 2001; 40(5): 513 - 521. [Abstract] [Full Text] [PDF]

				D. Karussis and O. Abramsky Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No Arch Neurol, August 1, 1999; 56(8): 1028 - 1032. [Full Text] [PDF]

				W Czerwenka, C Gruenwald, and D Conen Drug points: Aseptic meningitis after treatment with amoxicillin BMJ, June 5, 1999; 318(7197): 1521 - 1521. [Full Text]

				P. Picton and M. Chisholm Aseptic meningitis associated with high dose immunoglobulin: case report BMJ, November 8, 1997; 315(7117): 1203 - 1204. [Full Text]